Last updated 16 days ago
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
315 patients around the world
Available in Spain, United States, Chile, Argentina
Merck Sharp & Dohme LLC
5Research sites
315Patients around the world
This study is for people with
Skin cancer
Melanoma
Requirements for the patient
To 120 Years
All Gender
Medical requirements
Sites
Clínica Adventista Belgrano - CABA - Buenos Aires
Recruiting
Sanatorio Finochietto
Recruiting
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
CIDO SpA-Oncology
Recruiting
IC La Serena Research - La Serena
Recruiting
StudyMK-3475-02B
SponsorMerck Sharp & Dohme LLC
Conditions
Melanoma
Requirements
To 120 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT04305054
